{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:19:25Z","timestamp":1785529165270,"version":"3.56.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40261-020-00956-w","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T23:05:24Z","timestamp":1595286324000},"page":"915-926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review"],"prefix":"10.1007","volume":"40","author":[{"given":"Chang-Yu","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"956_CR1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s11096-019-00873-9","volume":"41","author":"JL Revuelta-Herrero","year":"2019","unstructured":"Revuelta-Herrero JL, Garc\u00eda-S\u00e1nchez R, Anguita-Velasco J, de Lorenzo-Pinto A, Ortega-Navarro C, Sanjurjo-S\u00e1ez M. Drug safety surveillance within a strategy for the management of non-chemotherapy drug-induced neutropenia. Int J Clin Pharm. 2019;41:1143\u20137.","journal-title":"Int J Clin Pharm."},{"key":"956_CR2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/asheducation-2017.1.187","volume":"2017","author":"BR Curtis","year":"2017","unstructured":"Curtis BR. Non\u2013chemotherapy drug\u2013induced neutropenia: key points to manage the challenges. Hematology. 2017;2017:187\u201393.","journal-title":"Hematology."},{"key":"956_CR3","first-page":"299","volume":"110","author":"E Andr\u00e8s","year":"2017","unstructured":"Andr\u00e8s E, Mourot-Cottet R, Maloisel F, S\u00e9verac F, Keller O, Vogel T, et al. Idiosyncratic drug-induced neutropenia and agranulocytosis. QJM An Int J Med. 2017;110:299\u2013305.","journal-title":"QJM An Int J Med."},{"key":"956_CR4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","volume":"146","author":"F Andersohn","year":"2007","unstructured":"Andersohn F, Konzen C, Edeltraut G. Annals of internal medicine review systematic review: agranulocytosis Induced by nonchemotherapy. Ann Intern Med. 2007;146:657\u201366.","journal-title":"Ann Intern Med"},{"key":"956_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/ehm.11.12","volume":"4","author":"E Andr\u00e8s","year":"2011","unstructured":"Andr\u00e8s E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol. 2011;4:143\u201351.","journal-title":"Expert Rev Hematol."},{"key":"956_CR6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(00)02125-5","volume":"355","author":"W Stock","year":"2000","unstructured":"Stock W, Hoffman R. White blood cells 1: non-malignant disorders. Lancet. 2000;355:1351\u20137.","journal-title":"Lancet"},{"key":"956_CR7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/jcm8091351","volume":"8","author":"V Andr\u00e8s","year":"2019","unstructured":"Andr\u00e8s V, Zulfiqar S, Mourot-Cottet G. State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies. J Clin Med. 2019;8:1351.","journal-title":"J Clin Med."},{"key":"956_CR8","first-page":"257","volume":"33","author":"C Benichou","year":"1991","unstructured":"Benichou C, Solal Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr Hematol. 1991;33:257\u201362.","journal-title":"Nouv Rev Fr Hematol."},{"key":"956_CR9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425255.2015.985649","volume":"11","author":"A Johnston","year":"2015","unstructured":"Johnston A, Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol. 2015;11:243\u201357.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"956_CR10","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/pds.2630020706","volume":"2","author":"DW Kaufman","year":"1993","unstructured":"Kaufman DW, Kelly JP, Levy M, Shapiro S. The drug etiology of agranulocytosis: an update of the international agranulocytosis and aplastic anemia study. Pharmacoepidemiol Drug Saf. 1993;2:S25\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"956_CR11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s12098-018-2687-z","volume":"85","author":"KL Hon","year":"2018","unstructured":"Hon KL, Chang M, Chong SC, Yuen YP, Tsui SKW. Adverse effects of azathioprine in a child and her mother with eczema. Indian J Pediatr. 2018;85:918\u20139.","journal-title":"Indian J Pediatr"},{"key":"956_CR12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","volume":"147","author":"J Berth-Jones","year":"2002","unstructured":"Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147:324\u201330.","journal-title":"Br J Dermatol"},{"key":"956_CR13","first-page":"e40","volume":"178","author":"W Yan","year":"2018","unstructured":"Yan W, Zhou YH, Wang L, Xiao J, Li W. NUDT15 polymorphism and severe azathioprine-induced myelosuppression in a Chinese man with pemphigus vulgaris. Br J Dermatol. 2018;178:e40\u20131.","journal-title":"Br J Dermatol"},{"key":"956_CR14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/dth.12114","volume":"27","author":"M Tichy","year":"2014","unstructured":"Tichy M, Urbanek J, Sternbersky J, Ditrichova D, Hercogova J. Life-threatening course of pemphigus vulgaris complicated by sepsis caused by azathioprine-induced bone marrow suppression, successfully managed with combination therapy. Dermatol Ther. 2014;27:183\u20136.","journal-title":"Dermatol Ther"},{"key":"956_CR15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4103\/0253-7613.100405","volume":"44","author":"B Laha","year":"2012","unstructured":"Laha B, Guha R, Hazra A. Multiple cutaneous neutropenic ulcers associated with azathioprine. Indian J Pharmacol. 2012;44:646\u20138.","journal-title":"Indian J Pharmacol."},{"key":"956_CR16","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1111\/1346-8138.14542","volume":"46","author":"YC Shih","year":"2019","unstructured":"Shih YC, Zou YR, Wang B, Zheng J, Pan M. Azathioprine-induced myelosuppression in two pemphigus vulgaris patients with homozygous polymorphism of NUDT15. J Dermatol. 2019;46:e59\u201361.","journal-title":"J Dermatol"},{"key":"956_CR17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","volume":"55","author":"AA Patel","year":"2006","unstructured":"Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55:369\u201389.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dsi.2013.07.001","volume":"32","author":"T-S Wang","year":"2014","unstructured":"Wang T-S, Chiu H-Y, Wu LS-H, Chu C-Y, Tsai T-F. Correlation of thiopurine methyltransferase and inosine triphosphate pyrophosphatase polymorphisms and adverse effects induced by azathioprine treatment in Taiwanese dermatology patients. Dermatologica Sin. 2014;32:13\u20138.","journal-title":"Dermatologica Sin"},{"key":"956_CR19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jama.2019.0709","volume":"321","author":"GJ Walker","year":"2019","unstructured":"Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, et al. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA. 2019;321:773\u201385.","journal-title":"JAMA"},{"key":"956_CR20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2217\/pgs.15.29","volume":"16","author":"RL Roberts","year":"2015","unstructured":"Roberts RL, Barclay ML. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16:891\u2013903.","journal-title":"Pharmacogenomics."},{"key":"956_CR21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/MEG.0000000000000564","volume":"28","author":"YJ Lee","year":"2016","unstructured":"Lee YJ, Hwang EH, Park JH, Shin J-H, Kang B, Kim S-Y. NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn\u2019s disease. Eur J Gastroenterol Hepatol. 2016;28:475\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"956_CR22","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/ibd.20522","volume":"14","author":"RM Rahhal","year":"2008","unstructured":"Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1678\u201382.","journal-title":"Inflamm Bowel Dis"},{"key":"956_CR23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13555-020-00360-4","volume":"10","author":"P-W Huang","year":"2020","unstructured":"Huang P-W, Tseng Y-H, Tsai T-F. Predictive value of NUDT15 variants on neutropenia among han chinese patients with dermatologic diseases: a single-center observational study. Dermatol Ther (Heidelb). 2020;10:263\u201371.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"956_CR24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","volume":"60","author":"M Cutolo","year":"2001","unstructured":"Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60:729\u201335.","journal-title":"Ann Rheum Dis"},{"key":"956_CR25","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1001\/jama.1988.03720240056034","volume":"259","author":"JL Shupack","year":"1988","unstructured":"Shupack JL, Webster GF. Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA J Am Med Assoc. 1988;259:3594\u20136.","journal-title":"JAMA J Am Med Assoc"},{"key":"956_CR26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0190-9622(97)70029-X","volume":"36","author":"EJ Primka","year":"1997","unstructured":"Primka EJ, Camisa C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol. 1997;36:815\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR27","first-page":"247.e2","volume":"77","author":"T-J Chen","year":"2017","unstructured":"Chen T-J, Chung W-H, Chen C-B, Hui RC-Y, Huang Y-H, Lu Y-T, et al. Methotrexate-induced epidermal necrosis: a case series of 24 patients. J Am Acad Dermatol. 2017;77:247.e2\u2013255.e2.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/21548331.1984.11702898","volume":"19","author":"M Turck","year":"1984","unstructured":"Turck M. Successful psoriasis treatment then sudden \u201ccytotoxicity\u201d. Hosp Pract. 1984;19:175\u20136.","journal-title":"Hosp Pract."},{"key":"956_CR29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jcpt.12060","volume":"38","author":"OM Al-Quteimat","year":"2013","unstructured":"Al-Quteimat OM, Al-Badaineh MA. Methotrexate and trimethoprim\u2013sulphamethoxazole: extremely serious and life-threatening combination. J Clin Pharm Ther. 2013;38:203\u20135.","journal-title":"J Clin Pharm Ther"},{"key":"956_CR30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1345\/aph.10184","volume":"35","author":"AJ Dixon","year":"2001","unstructured":"Dixon AJ, Wall GC. Probable colchicine-induced neutropenia not related to intentional overdose. Ann Pharmacother. 2001;35:192\u20135.","journal-title":"Ann Pharmacother"},{"key":"956_CR31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/15563650701779703","volume":"46","author":"G Eleftheriou","year":"2008","unstructured":"Eleftheriou G, Bacis G, Fiocchi R, Sebastiano R. Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. Clin Toxicol (Phila). 2008;46:827\u201330.","journal-title":"Clin Toxicol (Phila)"},{"key":"956_CR32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3349\/ymj.2008.49.1.171","volume":"49","author":"K-Y Lee","year":"2008","unstructured":"Lee K-Y, Kim DY, Chang JY, Bang D. Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Beh\u00e7et\u2019s disease. Yonsei Med J. 2008;49:171\u20133.","journal-title":"Yonsei Med J"},{"key":"956_CR33","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.clinthera.2017.05.115","volume":"39","author":"MF Tsoi","year":"2017","unstructured":"Tsoi MF, Cheung TT, Lam MPS, Cheung CL, Wong ICK, Hung IFN, et al. Safety of colchicine for gout: a ten-year survey of the Hong Kong population. Clin Ther. 2017;39:e36\u20137.","journal-title":"Clin Ther"},{"key":"956_CR34","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/j.1875-9114.1995.tb04352.x","volume":"15","author":"H Jick","year":"1995","unstructured":"Jick H, Myers MW, Dean AD. The risk of sulfasalazine- and mesalazine-associated blood disorders. Pharmacotherapy. 1995;15:176\u201381.","journal-title":"Pharmacotherapy."},{"key":"956_CR35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2230.1994.tb02699.x","volume":"19","author":"KK McKenna","year":"1994","unstructured":"McKenna KK, Burrows D. Leucopenia, thrombocytopenia and lymphadenopathy associated with sulphasalazine. Clin Exp Dermatol. 1994;19:419\u201320.","journal-title":"Clin Exp Dermatol"},{"key":"956_CR36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.anai.2013.09.028","volume":"112","author":"RA Orden","year":"2014","unstructured":"Orden RA, Timble H, Saini SS. Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. Am Coll Allergy Asthma Immunol. 2014;112:64\u201370.","journal-title":"Am Coll Allergy Asthma Immunol"},{"key":"956_CR37","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archderm.142.10.1337","volume":"142","author":"LY McGirt","year":"2006","unstructured":"McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol. 2006;142:1337\u201342.","journal-title":"Arch Dermatol"},{"key":"956_CR38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cpt.805","volume":"103","author":"M Wadelius","year":"2018","unstructured":"Wadelius M, Eriksson N, Kreutz R, Bondon-Guitton E, Iba\u00f1ez L, Carvajal A, et al. Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus. Clin Pharmacol Ther. 2018;103:843\u201353.","journal-title":"Clin Pharmacol Ther"},{"key":"956_CR39","first-page":"72","volume":"82","author":"CY Chew","year":"2020","unstructured":"Chew CY, Mar A, Nikpour M, Saracino AM. Hydroxychloroquine in dermatology: new perspectives on an old drug. Australas J Dermatol. 2020;82:72\u20139.","journal-title":"Australas J Dermatol"},{"key":"956_CR40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/archderm.1968.01610080067012","volume":"97","author":"D Chernof","year":"1968","unstructured":"Chernof D, Taylor KS. Hydroxychloroquine-induced agranulocytosis. Arch Dermatol. 1968;97:163\u20134.","journal-title":"Arch Dermatol"},{"key":"956_CR41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5152\/eurjrheum.2015.0028","volume":"3","author":"E Sames","year":"2016","unstructured":"Sames E, Paterson H, Li C. Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis. Eur J Rheumatol. 2016;3:91\u20132.","journal-title":"Eur J Rheumatol."},{"key":"956_CR42","first-page":"A311","volume":"41","author":"B Sharma","year":"2013","unstructured":"Sharma B, Manta D. 1218: hydroxychloroquine induced profound neutropenia with septic shock. Crit Care Med. 2013;41:A311\u20132.","journal-title":"Crit Care Med."},{"key":"956_CR43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archdermatol.2009.30","volume":"145","author":"A Shah","year":"2009","unstructured":"Shah A, Albrecht J, Boniila-Martinez Z, Okawa J, Rose M, Rosenbach M, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009;145:303\u20136.","journal-title":"Arch Dermatol"},{"key":"956_CR44","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma. J Clin Oncol Am Soc Clin Oncol. 2015;33:2803\u201311.","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"key":"956_CR45","doi-asserted-by":"crossref","unstructured":"Cohen PR. Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: Discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil. Dermatol Online J. 2018;24.","DOI":"10.5070\/D3244039360"},{"key":"956_CR46","first-page":"2006","volume":"5","author":"MR Johnson","year":"1999","unstructured":"Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006\u201311.","journal-title":"Clin Cancer Res"},{"key":"956_CR47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/archderm.1965.01600160066015","volume":"92","author":"CJ Dillaha","year":"1965","unstructured":"Dillaha CJ, Jansen GT, Honeycutt WM, Holt GA. Further studies with topical 5-fluorouracil. Arch Dermatol. 1965;92:410\u20137.","journal-title":"Arch Dermatol"},{"issue":"Suppl 1","key":"956_CR48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000252588","volume":"140","author":"M Erlanger","year":"1970","unstructured":"Erlanger M, Martz G, Ott F, Storck H, Rieder J, Kessler S. Cutaneous absorption and urinary excretion of 6-14C-5-fluorouracil ointment applicated in an ointment to healthy and diseased human skin. Dermatologica. 1970;140(Suppl 1):7\u201314.","journal-title":"Dermatologica."},{"key":"956_CR49","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/0003-4819-89-3-362","volume":"89","author":"GP Stoehr","year":"1978","unstructured":"Stoehr GP, Peterson AL. Systemic complication of local podophyllin therapy. Ann Intern Med. 1978;89:362\u20133.","journal-title":"Ann Intern Med."},{"key":"956_CR50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.47276\/lr.79.4.436","volume":"79","author":"RR Ranawaka","year":"2008","unstructured":"Ranawaka RR, Mendis S, Weerakoon HS. Dapsone-induced haemolytic anaemia, hepatitis and agranulocytosis in a leprosy patient with normal glucose-6-phosphate-dehydrogenase activity. Lepr Rev. 2008;79:436\u201340.","journal-title":"Lepr Rev"},{"key":"956_CR51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.47276\/lr.74.2.167","volume":"74","author":"RM Bhat","year":"2003","unstructured":"Bhat RM, Radhakrishnan K. A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient. Lepr Rev. 2003;74:167\u201370.","journal-title":"Lepr Rev"},{"key":"956_CR52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1515\/DMDI.2009.24.2-4.325","volume":"24","author":"RL Satarasinghe","year":"2009","unstructured":"Satarasinghe RL, Jayawardana MAR, De Silva GVTSK, Murugathas S, Riyaaz AAA, Wickrmasingha UDUK, et al. Total agranulocytosis caused by dapsone therapy for tuberculoid leprosy\u2014an unappreciated serious side effect of anti-leprosy treatment with clinical implications. Drug Metabol Drug Interact. 2009;24:325\u20139.","journal-title":"Drug Metabol Drug Interact."},{"key":"956_CR53","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/fcp.12287","volume":"31","author":"I Poto\u010dnjak","year":"2017","unstructured":"Poto\u010dnjak I, Liki\u0107 R, \u0160imi\u0107 I, Juri\u010di\u0107 Nahal D, \u010cegec I, Ganoci L, et al. Dapsone-induced agranulocytosis\u2014possible involvement of low-activity N-acetyltransferase 2. Fundam Clin Pharmacol. 2017;31:580\u20136.","journal-title":"Fundam Clin Pharmacol"},{"key":"956_CR54","first-page":"107","volume":"5","author":"Y Kobe","year":"2011","unstructured":"Kobe Y, Setoguchi D, Kitamura N. Dapsone-induced agranulocytosis leading to perianal abscess and death: a case report. J Med Case Rep BioMed Central Ltd. 2011;5:107.","journal-title":"J Med Case Rep BioMed Central Ltd"},{"key":"956_CR55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1751-553X.2007.00983.x","volume":"31","author":"M Besser","year":"2009","unstructured":"Besser M, Vera J, Clark J, Chitnavis D, Beatty C, Vassiliou G. Preservation of basophils in dapsone-induced agranulocytosis suggests a possible pathogenetic role for leucocyte peroxidases. Int J Lab Hematol. 2009;31:245\u20137.","journal-title":"Int J Lab Hematol."},{"key":"956_CR56","first-page":"717","volume":"12","author":"L Milkova","year":"2014","unstructured":"Milkova L, Hallermann C, Simon JC, Treudler R. Asymptomatische Dapson-induzierte Agranulozytose bei einem Patienten mit chronisch spontaner Urtikaria. JDDG J Ger Soc Dermatol. 2014;12:717\u201320.","journal-title":"JDDG J Ger Soc Dermatol."},{"key":"956_CR57","first-page":"205","volume":"76","author":"E Schmidt","year":"2005","unstructured":"Schmidt E, Kraensel R, Goebeler M, Sinkgraven R, Br\u00f6cker EB, Rzany B, et al. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis. 2005;76:205\u20139.","journal-title":"Cutis"},{"key":"956_CR58","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00105-004-0877-2","volume":"56","author":"TK Hoffmann","year":"2005","unstructured":"Hoffmann TK, von Schmiedeberg S, Wulferink M, Thier R, Bier H, Ruzicka T, et al. Dapsone-induced agranulocytosis. The role of xenobiotic-metabolizing enzymes demonstrated by a case report TT\u2014Dapson-induzierte Agranulozytose. Die Rolle fremdstoffmetabolisierender Enzyme am Beispiel einer Kasuistik. Hautarzt. 2005;56:673\u20137.","journal-title":"Hautarzt."},{"key":"956_CR59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(01)00360-2","volume":"162","author":"MD Coleman","year":"2001","unstructured":"Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology. 2001;162:53\u201360.","journal-title":"Toxicology."},{"key":"956_CR60","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/0306-3623(95)00029-1","volume":"26","author":"MD Coleman","year":"1995","unstructured":"Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol. 1995;26:1461\u20137.","journal-title":"Gen Pharmacol"},{"key":"956_CR61","first-page":"274","volume":"245","author":"J Uetrecht","year":"1988","unstructured":"Uetrecht J, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther. 1988;245:274\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"956_CR62","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1001\/archinte.1994.00420170135014","volume":"154","author":"D Kaufmann","year":"1994","unstructured":"Kaufmann D. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med. 1994;154:1983\u20134.","journal-title":"Arch Intern Med"},{"key":"956_CR63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1751-553X.2007.00967.x","volume":"30","author":"F Ahmed","year":"2008","unstructured":"Ahmed F, Kelsey PR, Shariff N. Lupus syndrome with neutropenia following minocycline therapy - A case report. Int J Lab Hematol. 2008;30:543\u20135.","journal-title":"Int J Lab Hematol."},{"key":"956_CR64","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00004836-199807000-00016","volume":"27","author":"C Berkelhammer","year":"1998","unstructured":"Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol. 1998;27:74\u20135.","journal-title":"J Clin Gastroenterol"},{"key":"956_CR65","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329\u201342.","journal-title":"Clin Ther"},{"key":"956_CR66","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1001\/jama.1979.03290440050030","volume":"241","author":"GL Fraser","year":"1979","unstructured":"Fraser GL, Beaulieu JT. Leukopenia secondary to sulfadiazine silver. JAMA. 1979;241:1928\u20139.","journal-title":"JAMA"},{"key":"956_CR67","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0305-4179(86)90136-1","volume":"12","author":"P Wilson","year":"1986","unstructured":"Wilson P, George R, Raine P. Topical silver sulphadiazine and profound neutropenia in a burned child. Burns. 1986;12:295\u20136.","journal-title":"Burns."},{"key":"956_CR68","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/BCR.0b013e3181a28c9b","volume":"30","author":"FW Fuller","year":"2009","unstructured":"Fuller FW. The side effects of silver sulfadiazine. J Burn Care Res. 2009;30:464\u201370.","journal-title":"J Burn Care Res."},{"key":"956_CR69","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4103\/ijd.IJD_131_17","volume":"63","author":"V Pai","year":"2018","unstructured":"Pai V, Ganavalli A, Kikkeri NN. Antifungal resistance in dermatology. Indian J Dermatol. 2018;63:361\u20138.","journal-title":"Indian J Dermatol."},{"key":"956_CR70","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/idoj.IDOJ_138_18","volume":"10","author":"RG Chaudhary","year":"2019","unstructured":"Chaudhary RG, Rathod SP, Jagati A, Zankat D, Brar AK, Mahadevia B. Oral antifungal therapy: emerging culprits of cutaneous adverse drug reactions. Indian Dermatol Online J. 2019;10:125\u201330.","journal-title":"Indian Dermatol Online J."},{"key":"956_CR71","first-page":"1196","volume":"140","author":"L-JMS Li","year":"1999","unstructured":"Li L-JMS, Miller J. Terbinafine-induced neutropenia. Br J Dermatol. 1999;140:1196\u20137.","journal-title":"Br J Dermatol."},{"key":"956_CR72","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0190-9622(98)70284-1","volume":"39","author":"DL Ornstein","year":"1998","unstructured":"Ornstein DL, Ely P. Reversible agranulocytosis associated with oral terbinafine for onychomycosis. J Am Acad Dermatol. 1998;39:1023\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR73","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0190-9622(98)70208-7","volume":"38","author":"AK Gupta","year":"1998","unstructured":"Gupta AK, Soori GS, Del Rosso JQ, Bartos PB, Shear NH. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol. 1998;38:765\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR74","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0190-9622(09)80049-2","volume":"31","author":"MJ Kovacs","year":"1994","unstructured":"Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol. 1994;31:806.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR75","first-page":"411","volume":"31","author":"B Kantarcioglu","year":"2014","unstructured":"Kantarcioglu B, Turkoz HK, Yilmaz G, Pepedil Tanrikulu F, Kaygusuz Atagunduz I, Adiguzel C, et al. Aplastic anemia associated with oral terbinafine: a case report and review of the literature. Turk J Haematol Off J Turk Soc Haematol. 2014;31:411\u20136.","journal-title":"Turk J Haematol Off J Turk Soc Haematol."},{"key":"956_CR76","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2001.117520","volume":"45","author":"C Aguilar","year":"2001","unstructured":"Aguilar C, Mueller KK. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient. J Am Acad Dermatol. 2001;45:632\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"956_CR77","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","volume":"126","author":"NS Ryder","year":"1992","unstructured":"Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(Suppl):2\u20137.","journal-title":"Br J Dermatol"},{"key":"956_CR78","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jdcr.2019.06.009","volume":"5","author":"B Schultz","year":"2019","unstructured":"Schultz B, Culton D. A case of late-onset neutropenia secondary to rituximab in a patient with mucous membrane pemphigoid. JAAD Case Rep. 2019;5:715\u20139.","journal-title":"JAAD Case Rep"},{"key":"956_CR79","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ced.13726","volume":"44","author":"BL Adler","year":"2019","unstructured":"Adler BL, Crew AB, Woodley DT. Early-onset neutropenia after rituximab therapy for bullous pemphigoid. Clin Exp Dermatol. 2019;44:334\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"956_CR80","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2007.07800.x","volume":"156","author":"MSY Goh","year":"2007","unstructured":"Goh MSY, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol. 2007;156:990\u20136.","journal-title":"Br J Dermatol"},{"key":"956_CR81","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2133.2007.08189.x","volume":"157","author":"R Rios-Fern\u00e1ndez","year":"2007","unstructured":"Rios-Fern\u00e1ndez R, Gutierrez-Salmer\u00f3n MT, Callejas-Rubio J-L, Fern\u00e1ndez-Pugnaire M, Ortego-Centeno N. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol. 2007;157:1271\u20133.","journal-title":"Br J Dermatol"},{"key":"956_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21767\/1989-5216.1000208","volume":"9","author":"H Khosravi","year":"2017","unstructured":"Khosravi H, Abdollahi M, Badakhsh M, Soori T, Jafari M, Bae G, et al. Rituximab induced neutropenia in a patient with bullous pemphigoid. Arch Med. 2017;9:1\u20132.","journal-title":"Arch Med."},{"key":"956_CR83","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1177\/0961203318777116","volume":"27","author":"I Parodis","year":"2018","unstructured":"Parodis I, S\u00f6der F, Faustini F, Kasza Z, Samuelsson I, Zickert A, et al. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus\u2014distinct roles of BAFF and APRIL. Lupus. 2018;27:1470\u20138.","journal-title":"Lupus."},{"key":"956_CR84","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","volume":"89","author":"O Wolach","year":"2010","unstructured":"Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore). 2010;89:308\u201318.","journal-title":"Medicine (Baltimore)."},{"key":"956_CR85","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1136\/ard.2006.056176","volume":"65","author":"S Rajakulendran","year":"2006","unstructured":"Rajakulendran S, Gadsby K, Allen D, O\u2019Reilly S, Deighton C. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis. 2006;65:1678\u20139.","journal-title":"Ann Rheum Dis"},{"key":"956_CR86","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1365-2230.2009.03665.x","volume":"34","author":"J Jordan","year":"2009","unstructured":"Jordan J, Bieber T, Wilsmann-Theis D. Rapid remission of psoriasis with reversible leucopenia after two injections with adalimumab. Clin Exp Dermatol. 2009;34:1004\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"956_CR87","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.annder.2008.01.011","volume":"135","author":"I Lahbabi","year":"2008","unstructured":"Lahbabi I, Adamski H, Le Jean S, Cannieux V, Polard E, Chevrant-Breton J. Neutropenia and thrombocytopenia in a patient presenting psoriasis treated with etanercept. Ann Dermatol Venereol. 2008;135:409\u201310.","journal-title":"Ann Dermatol Venereol"},{"key":"956_CR88","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2036.2012.05189.x","volume":"36","author":"T Bessissow","year":"2012","unstructured":"Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36:312\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"83\u201398","key":"956_CR89","first-page":"e4","volume":"75","author":"PCM Van De Kerkhof","year":"2016","unstructured":"Van De Kerkhof PCM, Griffiths CEM, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(83\u201398):e4.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR90","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345\u201356.","journal-title":"N Engl J Med"},{"key":"956_CR91","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318\u201328.","journal-title":"N Engl J Med"},{"key":"956_CR92","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/blood.V98.12.3309","volume":"98","author":"SB Forlow","year":"2001","unstructured":"Forlow SB, Schurr JR, Kolls JK, Bagby GJ, Schwarzenberger PO, Ley K. Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice. Blood. 2001;98:3309\u201314.","journal-title":"Blood"},{"key":"956_CR93","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1673877","author":"K Tegtmeyer","year":"2019","unstructured":"Tegtmeyer K, Zhao J, Maloney NJ, Atassi G, Beestrum M, Lio PA. Off-label studies on tofacitinib in dermatology: a review. J Dermatolog Treat. 2019. https:\/\/doi.org\/10.1080\/09546634.2019.1673877.","journal-title":"J Dermatolog Treat."},{"key":"956_CR94","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10067-018-4299-4","volume":"38","author":"F Huang","year":"2019","unstructured":"Huang F, Luo Z-C. Adverse drug events associated with 5\u00a0mg versus 10\u00a0mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2019;38:523\u201334.","journal-title":"Clin Rheumatol."},{"key":"956_CR95","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","volume":"56","author":"H Schulze-Koops","year":"2016","unstructured":"Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology. 2016;56:46\u201357.","journal-title":"Rheumatology."},{"key":"956_CR96","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/120347540200600508","volume":"6","author":"ES Friedman","year":"2002","unstructured":"Friedman ES, LaNatra N, Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg. 2002;6:449\u201359.","journal-title":"J Cutan Med Surg."},{"key":"956_CR97","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0190-9622(85)80497-7","volume":"13","author":"AJ Wishner","year":"1985","unstructured":"Wishner AJ, Milburn PB. Meclofenamate sodium-induced agranulocytosis and suppression of erythropoiesis. J Am Acad Dermatol. 1985;13:1052\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR98","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1001\/archinte.1993.00410180065007","volume":"153","author":"BL Strom","year":"1993","unstructured":"Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M, Lundin FEJ. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med. 1993;153:2119\u201324.","journal-title":"Arch Intern Med"},{"key":"956_CR99","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00210-019-01774-4","volume":"393","author":"S Klose","year":"2020","unstructured":"Klose S, Pflock R, K\u00f6nig IR, Linder R, Schwaninger M. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:681\u201390.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"956_CR100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1056\/NEJM198603063141006","volume":"314","author":"SW Mamus","year":"1986","unstructured":"Mamus SW, Burton JD, Groat JD, Schulte DA, Lobell M, Zanjani ED. Ibuprofen-associated pure white-cell aplasia. N Engl J Med. 1986;314:624\u20135.","journal-title":"N Engl J Med"},{"key":"956_CR101","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2165\/00003495-199753030-00003","volume":"53","author":"CE Orfanos","year":"1997","unstructured":"Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53:358\u201388.","journal-title":"Drugs."},{"key":"956_CR102","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4103\/0378-6323.120721","volume":"79","author":"R Sarkar","year":"2013","unstructured":"Sarkar R, Chugh S, Garg VK. Acitretin in dermatology. Indian J Dermatol Venereol Leprol. 2013;79:759\u201371.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"956_CR103","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1046\/j.1365-2133.2003.05333.x","volume":"148","author":"TA Chave","year":"2003","unstructured":"Chave TA, Mortimer NJ, Hutchinson PE. Agranulocytosis and total scalp alopecia following acitretin. Br J Dermatol. 2003;148:1063\u20134.","journal-title":"Br J Dermatol"},{"key":"956_CR104","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1525-1470.2007.00468.x","volume":"24","author":"MA Ozdemir","year":"2007","unstructured":"Ozdemir MA, Kose M, Karakukcu M, Ferahbas A, Patiroglu T, Koklu E. Isotretinoin-induced agranulocytosis. Pediatr Dermatol. 2007;24:425\u20136.","journal-title":"Pediatr Dermatol"},{"key":"956_CR105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(88)80169-5","volume":"18","author":"M Waisman","year":"1988","unstructured":"Waisman M. Agranulocytosis from isotretinoin. J Am Acad Dermatol. 1988;18:395\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR106","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archderm.1987.01660270025003","volume":"123","author":"SM Olbricht","year":"1987","unstructured":"Olbricht SM, Ave B, Griffiths CEM, Street P. Leukopenia and neutropenia associated with isotretinoin therapy. Arch Dermatol. 1987;123:293\u20135.","journal-title":"Arch Dermatol"},{"key":"956_CR107","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2019.06.025","volume":"82","author":"JS Barbieri","year":"2020","unstructured":"Barbieri JS, Shin DB, Wang S, Margolis DJ, Takeshita J. The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time. J Am Acad Dermatol. 2020;82:72\u20139.","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00956-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T11:36:45Z","timestamp":1723289805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00956-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":107,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00956-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"21 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding or sponsorship was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Chang-Yu Hsieh has no conflict of interest to disclose. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli-Lilly, Galderma, Janssen-Cilag, Merck Sharp & Dohme, Novartis International AG, Pfizer Inc., and UCB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This article is based on previously conducted studies. Searching strategies are specified in the Methods\u00a0of Literature Search section.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"C-YH conducted the literature search and drafted the manuscript.\u00a0T-FT provided the idea of this review and made final revisions of this article.\u00a0","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}